Oncolytics Biotech Inc ONCY

TIME has arrived on the Making of a Breast Cancer Vaccine

[Noteable]

The Ocotober 2022 issue of TIME Magazine has published an article entitled "The Race to Make a Vaccine for Breast Cancer" spotlights the increased activity in the development of a cancer vaccine for breast cancer. The article describes what ONCY already knows in that the combination of a oncolytic virus/vaccine with an immune checkpoint inhibitor can significantly improve overall treatment outcomes for patients on this I/O combination therapy.

We also know that ONCY's IMMUNE MOLECULE PLATFORM TECHNOLOGY in pelareorep is in advanced Phase 2 clinical testing with the Bracelet-1 breast cancer trial now completed with the trial data now before both Merck KGaA and Pfizer for review and decisions on their first mover advantage.   

[Noteable]

Should read .... "The October 2022 issue of TIME Magazine has published an article entitled "The Race to Make a Vaccine for Breast Cancer" which spotlights the increased activity occurring in the development of a cancer vaccine for breast cancer. "

[Noteable]

Yesterday ABC news ran the following piece on the development of a potential breast cancer vaccine for HER2+ breast cancers which represent approximately 15% of all breast cancers. In contrast ONCY's oncolytic virus/vaccine pelareorep has been trialed in HER2- breast cancer which represents approximately 80% of all breast cancers. https://abcnews.go.com/GMA/Wellness/video/breast-cancer